Insmed Incorporated
INSM
Kedudukan dalam Saham
#1110
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Harga Saham
$95.88
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$20.94B
Perubahan (1 hari)
0.61%
Perubahan (1 tahun)
-42.00%
Negara
US
Perdagangan Insmed Incorporated (INSM)
Kategori
Healthcare
Hasil untuk Insmed Incorporated (INSM)
Hasil pada Jun 2026 TTM: $1.14B
Menurut laporan kewangan terkini daripada Insmed Incorporated, hasil semasa syarikat (TTM) ialah $1.14B. Pada tahun 2023, syarikat memperoleh hasil sebanyak $305.21M peningkatan berbanding hasil pada tahun 2022 iaitu $245.36M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Insmed Incorporated dari 2000 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $1.14B | 212.79% |
| 2024 | $363.71M | 19.17% |
| 2023 | $305.21M | 24.39% |
| 2022 | $245.36M | 30.19% |
| 2021 | $188.46M | 14.63% |
| 2020 | $164.41M | 20.48% |
| 2019 | $136.47M | 1,287.56% |
| 2018 | $9.84M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $11.50M | 0.00% |
| 2013 | $11.50M | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $4.42M | -36.18% |
| 2010 | $6.92M | -33.28% |
| 2009 | $10.37M | -11.33% |
| 2008 | $11.70M | 55.39% |
| 2007 | $7.53M | 659.74% |
| 2006 | $991.00K | 656.49% |
| 2005 | $131.00K | -4.38% |
| 2004 | $137.00K | -8.67% |
| 2003 | $150.00K | -92.33% |
| 2002 | $1.96M | 560.47% |
| 2001 | $296.00K | 393.33% |
| 2000 | $60.00K | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 1,009.70% |
US
|
|
| $2.23B | 95.84% |
US
|
|
| $15.74B | 1,283.95% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 429.28% |
NL
|
